CRISPR/Cas9 genome editing has become widely used due to its simplicity and versatility, and the CRISPR technology has been adapted for diverse applications aside from genome editing. As a leader in gene synthesis and genome editing, and through our partnership with Feng Zhang's laboratory at the Broad Institute of MIT and Harvard*, GenScript offers validated CRISPR products, services and resources to help you harness the power of CRISPR genome editing for your research.

One-Stop Solution for Your Genome Editing Needs
Licensed from the Broad Institute and ERS Genomics

Popular CRISPR Services

Mouse Polyclonal Antibody Generation
CRISPR gRNA Plasmids

Licensed from the Feng Zhang Laboratory at the Broad Institute

Learn More

A powerful tool for creating gene knock-ins and knock-outs

Learn More
HDR Knock-in Templates
HDR Knock-in Templates

ssDNA and dsDNA HDR donor templates for effective gene knock-in

Learn More
CRISPR Cell Lines
CRISPR Cell Lines

Genetically modified cell line in any mammalian cell line and targeting any gene.

Learn More
Microbial Gene Editing
Microbial Gene Editing

Highly efficient, seamless genome editing in E.coli using CRISPR technology

Learn More
CRISPR gRNA Libraries
CRISPR gRNA Libraries

Genome-wide gRNA libraries for efficient screening

Learn More


Recommended Resources

Featured Webinar | CRISPR Based CAR-T Cell Editing: Large gene knock-ins in human T cells using non-viral HDR templates

Dr. Theo Roth from Marson Lab, UCSF introduces the advantages of a new CRISPR based method that allows for the insertion of large DNA sequences (>1Kb) in primary T cells without a virus.

CRISPR Frequently Asked Questions

Get in Touch
with GenScript
CRISPR Experts

Get in Touch with GenScript Custom CRISPR Experts
Please enter a valid first name.
Please enter a valid last name.
Please enter a valid email name.
Please select a valid industry.
Please enter a valid institution/company.
Please select a valid country.
Please select a valid Zipcode.
Please enter a message in the textarea.

Legal Statement of GenCRISPR™ Services and Products
(Updated on April 27, 2021):

  1. GenCRISPR™ services and products are covered under US 10,946,108, US 10,930,367, US 10,781,444, US 10,711,285, US 10,577,630, US 9,840,713, US 9,822,372, US 8,999,641, US 8,993,233, US 8,945,839, US 8,932,814, US 8,906,616, US 8,895,308, US 8,889,418, US 8,889,356, US 8,871,445, US 8,865,406, US 8,795,965, US 8,771,945, US 8,697,359 and foreign equivalents and licensed from Broad Institute, Inc. Cambridge, Massachusetts, and US 10,000,772, US 10,113,167, US 10,227,611, US 10,266,850, US 10,301,651, US 10,308,961, US 10,337,029, US 10,351,878, US 10,358,658, US 10,358,659, US 10,385,360, US 10,400,253, US 10,407,697, US 10,415,061, US 10,421,980, US 10,428,352, US 10,443,076, US 10,487,341, US 10,513,712, US 10,519,467, US 10,526,619, US 10,533,190, US 10,550,407, US 10,563,227, US 10,570,419, US 10,577,631, US 10,597,680, US 10,612,045, US 10,626,419, US 10,640,791, US 10,669,560, US 10,676,759, US 10,752,920, US 10,774,344, US 10,793,878, US 10,900,054 and foreign equivalents and licensed from ERS Genomics Limited.
  2. The products and the reagents generated from these services shall be used as tools for research purposes, and shall exclude (a) any human or clinical use, including, without limitation, any administration into humans or any diagnostic or prognostic use, (b) any human germline modification, including modifying the DNA of human embryos or human reproductive cells, (c) any in vivo veterinary or livestock use, or (d) the manufacture, distribution, importation, exportation, transportation, sale, offer for sale, marketing, promotion or other exploitation or use of, or as, a testing service, therapeutic or diagnostic for humans or animals.
  3. The purchase of the GenCRISPR™ Services and Products coveys to the purchaser the limited, non-transferable right to use the products purchased and the reagents generated from GenCRISPR™ services and any related material solely for Research Purposes only, not for any Commercial Purposes.


Do you like the current new website?